Episode
Deep Dive: The PFAS Substitution Risk Paradox in Medical Devices
- Podcast
- Let's Talk Risk! Podcast
- Published
- Sep 4, 2026
- Duration seconds
- 1226
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/deep-dive-the-pfas-substitution-risk-paradox-in-medical-devices.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices. What happens when pressure to eliminate a material creates greater risk for the patient? This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers , and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category. Key highlights covered in the audio: * Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices. * FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE. * Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety. * This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications. * The decision belongs inside risk management. Under ISO 14971 , the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed. * A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material. Keywords: PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management 🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived…